Literature DB >> 12617032

[Therapeutic strategy for fibrotic diseases by regulating the expression of collagen-specific molecular chaperone HSP47].

Kazuhiro Nagata1.   

Abstract

Through disruption of the hsp47 gene in mice, we found that HSP47, a collagen-specific molecular chaperone residing in the endoplasmic reticulum, is essential for mouse development. Improper triple helix formation was observed in hsp47-null embryos, and no collagen fibrils in the mesenchyme or basement membranes between the mesenchyme and epithelial cell layers were seen in those mice, which resulted in embryonic lethality. Interestingly, constitutive expression of HSP47 is always correlated with that of collagens in various cells or tissues. HSP47 is markedly up-regulated during the progression of fibrosis in the liver, kidney, lung, and so on. A preliminary experiment showed that down-regulation of HSP47 caused the reduction in the progression of fibrosis by down-regulating the accumulation of collagens in the tissues, which suggests a novel strategy for the therapy of fibrotic diseases including liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12617032     DOI: 10.1254/fpj.121.4

Source DB:  PubMed          Journal:  Nihon Yakurigaku Zasshi        ISSN: 0015-5691


  3 in total

1.  Heat shock proteins modulate keloid formation.

Authors:  Serhat Totan; Anthony Echo; Eser Yuksel
Journal:  Eplasty       Date:  2011-04-29

2.  New insights into therapeutic strategies for the treatment of peritoneal fibrosis: learning from histochemical analyses of animal models.

Authors:  Mineaki Kitamura; Tomoya Nishino; Yoko Obata; Yoshiyuki Ozono; Takehiko Koji; Shigeru Kohno
Journal:  Acta Histochem Cytochem       Date:  2014-07-16       Impact factor: 1.938

3.  SERPINH1 overexpression in clear cell renal cell carcinoma: association with poor clinical outcome and its potential as a novel prognostic marker.

Authors:  Yijun Qi; Yue Zhang; Zhiqiang Peng; Lei Wang; Kaizhen Wang; Duiping Feng; Junqi He; Junfang Zheng
Journal:  J Cell Mol Med       Date:  2017-12-14       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.